Millendo Therapeutics, Inc. (51) | Human Resources (30)

Browse by Subcategory

Recent Contracts

Tempest Therapeutics, Inc. Amended and Restated 2019 Equity Incentive Plan (Filed With SEC on June 21, 2022)
Executive Employment Agreement, dated January 12, 2022, by and between the Company and Nicholas Maestas (Filed With SEC on May 13, 2022)
Separation from Employment, by and between Millendo Therapeutics US, Inc. and Julia C. Owens, Ph.D., dated January 27, 2021 (Filed With SEC on March 29, 2021)
Consulting Agreement, by and between the Registrant and Jeffery Brinza, dated August 23, 2019 (Filed With SEC on November 13, 2019)
Executive Employment Agreement, dated January 12, 2022, by and between the Company and Samuel Whiting, M.D., Ph.D (Filed With SEC on May 13, 2022)
Executive Employment Agreement, dated January 12, 2022, by and between the Company and Thomas Dubensky (Filed With SEC on May 13, 2022)
Executive Employment Agreement, dated January 12, 2022, by and between the Company and Stephen Brady (Filed With SEC on May 13, 2022)
Form of Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on March 29, 2022)
Employment Agreement, dated July 7, 2021, by and between the Company and Samuel Whiting, M.D., Ph.D (Filed With SEC on July 7, 2021)
Employment Agreement, dated July 7, 2021, by and between the Company and Thomas Dubensky, Ph.D (Filed With SEC on July 7, 2021)
Employment Agreement, dated July 7, 2021, by and between the Company and Stephen Brady (Filed With SEC on July 7, 2021)
Amended and Restated Employment Agreement between Jennifer Minai-Azary and Millendo Therapeutics US, Inc., dated of January 27, 2021 (Filed With SEC on March 29, 2021)
Amended and Restated Employment Agreement between Louis Arcudi III and Millendo Therapeutics US, Inc., dated as of January 27, 2021 (Filed With SEC on March 29, 2021)
Separation Agreement, by and among Millendo Therapeutics, Inc. and Ryan K. Zeidan, dated January 25, 2021 (Filed With SEC on January 28, 2021)
Amendment to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on June 23, 2020)
Amendment to the Millendo Therapeutics, Inc. (formerly OvaScience, Inc.) 2012 Stock Incentive Plan (Filed With SEC on June 23, 2020)
Employment Agreement between Christophe Arbet-Engels and Millendo Therapeutics US, Inc., dated as of February 5, 2020 (Filed With SEC on March 11, 2020)
Form of Inducement Nonqualified Stock Option Agreement subject to the terms of the 2019 Equity Incentive Plan (Filed With SEC on March 11, 2020)
Form of Stock Option Agreement under the Sub Plan for French Residents under 2019 Equity Incentive Plan (Filed With SEC on March 11, 2020)
Form of Inducement Nonqualified Stock Option Agreement subject to the terms of the OvaScience 2012 Stock Incentive Plan (Filed With SEC on March 11, 2020)
Employment Agreement, by and between Millendo Therapeutics US, Inc. and Tamara Joseph, dated July 11, 2019 (Filed With SEC on November 13, 2019)
Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Ryan Zeidan, dated August 16, 2019 (Filed With SEC on November 13, 2019)
Form of RSU Grant Package under 2019 Equity Incentive Plan (Filed With SEC on August 12, 2019)
Form of Option Grant Package under 2019 Equity Incentive Plan (Filed With SEC on August 12, 2019)
Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Jeffery M. Brinza, dated May 23, 2019 (Filed With SEC on August 12, 2019)
Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Louis Arcudi III, dated June 19, 2019 (Filed With SEC on August 12, 2019)
Amended and Restated Employment Agreement, by and between Millendo Therapeutics US, Inc. and Julia C. Owens, Ph.D., dated June 19, 2019 (Filed With SEC on August 12, 2019)
2019 Equity Incentive Plan (Filed With SEC on June 13, 2019)
Form of Stock Option Agreement under the Millendo Therapeutics, Inc. 2012 Stock Incentive Plan (Filed With SEC on April 1, 2019)
Millendo Therapeutics, Inc. 2012 Stock Incentive Plan, as amended (Filed With SEC on April 1, 2019)